Anapa

Researchers are evaluating the effectiveness and tolerability of Lusefi4, a medication for adults with type 2 diabetes, in a real-world clinical setting. This observational study focuses on how well Luseogliflozin controls blood sugar levels, measured by glycated hemoglobin, along with its effects on metabolic and hemodynamic health over approximately six months. Participants will have started treatment with 2.5 mg of Lusefi4 once daily as part of their routine care. If needed, their doctors may increase the dose to 5 mg once daily. The study is single-arm, meaning all participants receive Lusefi4, with no comparison group. The observation period lasts about six months to assess the drug's impact. During the study, patients will be monitored for blood sugar control and other health parameters like blood pressure and kidney function. Data will be collected from routine clinical visits, including laboratory tests for glycated hemoglobin and kidney function. Researchers will track treatment adherence and any side effects to understand Lusefi4's effectiveness and tolerability in everyday medical practice.